Kintara Therapeutics Inc (NASDAQ:KTRA) does about 9.48M shares in volume on a normal day but saw 1560988 shares change hands in the recent trading day. The company now has a market cap of 12.47M USD. Its current market price is $0.23, marking a decrease of -2.04% compared to the previous close of $0.23. The 52 week high reached by this stock is $5.00 whilst the lowest price level in 52 weeks is $0.08.
Kintara Therapeutics Inc (KTRA) has a 20-day trading average at $0.2029 and the current price is -95.49% off the 52-week high compared with 178.15% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2366 and its 200-day simple moving average is $0.1893. If we look at the stock’s price movements over the week, volatility stands at 12.96%, which decreases to 11.54% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.27 to suggest the stock is neutral.
The consensus objective for the share price is $14.00, suggesting that the stock has a potential upside of 98.36% over the period.
FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is 10.49%, -4.54%, and 18.37% away from its SMA20, SMA50, and SMA200 respectively, with the KTRA price moving above the 50-day SMA on current market day. Kintara Therapeutics Inc (KTRA) stock is up 7.49% over the week and 3.73% over the past month. Its price is 32.84% year-to-date and -93.81% over the past year.
To reach the target analysts have set, the stock logically needs to grow 98.36 percent from here.
Outstanding shares total 55.37M with insiders holding 0.12% of the shares and institutional holders owning 1.48% of the company’s common stock. The company has a return on investment of -160.62% and return on equity of -192.23%. The beta has a value of 0.82.
